Cited by 1,462Cancer, Hypoxia, and MetabolismCancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses

Open access

Ho, Ping-Chih, Bihuniak, Jessica Dauz, Macintyre, Andrew N., Staron, Matthew, Liu, Xiaojing, Amezquita, Robert, Tsui, Yao-Chen, Cui, Guoliang, Micevic, Goran, Perales, Jose C., Kleinstein, Steven H., Abel, E. Dale, Insogna, Karl L., Feske, Stefan, Locasale, Jason W., Bosenberg, Marcus W., Rathmell, Jeffrey C., Kaech, Susan M.·2015·Cell

DOI 10.1016/j.cell.2015.08.012PMC PMC4567953

Open this paper in CoChat — free account Open PDF

Abstract

Activated T cells engage aerobic glycolysis and anabolic metabolism for growth, proliferation, and effector functions. We propose that a glucose-poor tumor microenvironment limits aerobic glycolysis in tumor-infiltrating T cells, which suppresses tumoricidal effector functions. We discovered a new role for the glycolytic metabolite phosphoenolpyruvate (PEP) in sustaining T cell receptor-mediated Ca(2+)-NFAT signaling and effector functions by repressing sarco/ER Ca(2+)-ATPase (SERCA) activity. Tumor-specific CD4 and CD8 T cells could be metabolically reprogrammed by increasing PEP production through overexpression of phosphoenolpyruvate carboxykinase 1 (PCK1), which bolstered effector functions. Moreover, PCK1-overexpressing T cells restricted tumor growth and prolonged the survival of melanoma-bearing mice. This study uncovers new metabolic checkpoints for T cell activity and demonstrates that metabolic reprogramming of tumor-reactive T cells can enhance anti-tumor T cell responses, illuminating new forms of immunotherapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.cell.2015.08.012

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
T cell exhaustion
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062 · cited 1×
“T cells displaying such properties are commonly referred to as ‘‘functionally exhausted’’ (Wherry, 2011).”
Background
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate
Ward, P. S., & Thompson, C. B. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.014 · Cited by 3,233
Posttranscriptional Control of T Cell Effector Function by Aerobic Glycolysis
Chang, C.-H., Curtis, J. D., Maggi, L. B., Faubert, B., Villarino, A. V., O’Sullivan, D., Huang, S. C.-C., van der Windt, G. J. W., Blagih, J., Qiu, J., et al. (2013) · Cell · doi:10.1016/j.cell.2013.05.016 · Cited by 2,204

Flagged first, then by citations

Show all 47 references

Sorted by citations

Items 601–700 of 1,000

Mitochondrial dysfunction triggers actin polymerization necessary for rapid glycolytic activation
Chakrabarti, R., Fung, T. S., Kang, T., Elonkirjo, P. W., Suomalainen, A., Usherwood, E. J., & Higgs, H. N. (2022) · The Journal of Cell Biology · doi:10.1083/jcb.202201160 · Cited by 44
Metabolic advantages of regulatory T cells dictated by cancer cells
Kondo, M., Kumagai, S., & Nishikawa, H. (2023) · International Immunology · doi:10.1093/intimm/dxad035 · Cited by 42
Manipulating the tumor microenvironment by adoptive cell transfer of CAR T-cells
Gowrishankar, K., Birtwistle, L., & Micklethwaite, K. P. (2018) · Mammalian Genome · doi:10.1007/s00335-018-9756-5 · Cited by 43
How DNA methylation affects the Warburg effect
Zhu, X., Xuan, Z., Chen, J., Li, Z., Zheng, S., & Song, P. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.45420 · Cited by 42
Engineering Next-Generation CAR-T Cells: Overcoming Tumor Hypoxia and Metabolism
Gao, T. A., & Chen, Y. Y. (2022) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-092120-092914 · Cited by 41
CAR-T Therapy in GBM: Current Challenges and Avenues for Improvement
Pant, A., & Lim, M. K. (2023) · Cancers · doi:10.3390/cancers15041249 · Cited by 39
The Interplay between T Cells and Cancer: The Basis of Immunotherapy
Chen, C., Liu, X., Chang, C., Wang, H. Y., & Wang, R. (2023) · Genes · doi:10.3390/genes14051008 · Cited by 42
Self-citation
Acid affairs in anti-tumour immunity
Cappellesso, F., Mazzone, M., & Virga, F. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03520-0 · Cited by 44
Regulation of mTOR, Metabolic Fitness, and Effector Functions by Cytokines in Natural Killer Cells
Viel, S., Besson, L., Marotel, M., Walzer, T., & Marçais, A. (2017) · Cancers · doi:10.3390/cancers9100132 · Cited by 38
New Immunometabolic Strategy Based on Cell Type-Specific Metabolic Reprogramming in the Tumor Immune Microenvironment
Sung, J., & Cheong, J. (2022) · Cells · doi:10.3390/cells11050768 · Cited by 40
Amino acids and RagD potentiate mTORC1 activation in CD8 + T cells to confer antitumor immunity
Zhang, Y., Hu, H., Liu, W., Yan, S., Li, Y., Tan, L., Chen, Y., Liu, J., Peng, Z., Yuan, Y., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002137 · Cited by 37
A novel strategy to fuel cancer immunotherapy: targeting glucose metabolism to remodel the tumor microenvironment
Liu, X., Zhao, Y., Wu, X., Liu, Z., & Liu, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.931104 · Cited by 41
Self-citation
mTOR inhibitor, gemcitabine and PD-L1 antibody blockade combination therapy suppresses pancreatic cancer progression via metabolic reprogramming and immune microenvironment remodeling in Trp53flox/+LSL-KrasG12D/+Pdx-1-Cre murine models
Qiu, J., Feng, M., Yang, G., Cao, Z., Liu, Y., You, L., & Zhang, T. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.216020 · Cited by 38
Targeting MondoA–TXNIP restores antitumour immunity in lactic-acid-induced immunosuppressive microenvironment
Xu, N., Zhu, Y., Han, Y., Liu, Q., Tong, L., Li, Y., Chen, Z., Shao, S., He, W., Li, M., et al. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01347-1 · Cited by 47
Natural killer cell metabolism
Kobayashi, T., & Mattarollo, S. R. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.11.021 · Cited by 37
In Situ Imaging of Formaldehyde in Live Mice with High Spatiotemporal Resolution Reveals Aldehyde Dehydrogenase-2 as a Potential Target for Alzheimer’s Disease Treatment
Tao, R., Liao, M., Wang, Y., Wang, H., Tan, Y., Qin, S., Wei, W., Tang, C., Liang, X., Han, Y., et al. (2021) · Analytical Chemistry · doi:10.1021/acs.analchem.1c04520 · Cited by 38
Dual‐Targeted Nanoreactors and Prodrugs: Hydrogen Peroxide Triggers Oxidative Damage and Prodrug Activation for Synergistic Elimination of Cancer Cells
Jo, S., Kim, H. S., Won, M., Champanhac, C., Kim, J. S., Wurm, F. R., & Landfester, K. (2022) · Advanced Functional Materials · doi:10.1002/adfm.202200791 · Cited by 38
Immunotherapy: an emerging modality to checkmate brain metastasis
Ahmad, A., Κhan, P., Rehman, A. U., Batra, S. K., & Nasser, M. W. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01818-7 · Cited by 38
Intermittent fasting induced ketogenesis inhibits mouse epithelial ovarian cancer by promoting antitumor T cell response
Udumula, M. P., Singh, H., Rashid, F., Poisson, L., Tiwari, N., Dimitrova, I. K., Hijaz, M., Gogoi, R. P., Swenor, M., Munkarah, A. R., et al. (2023) · iScience · doi:10.1016/j.isci.2023.107839 · Cited by 47
Metabolic reprogramming and apoptosis sensitivity: Defining the contours of a T cell response
Voss, K., Larsen, S. E., & Snow, A. L. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.08.033 · Cited by 38
Dendritic cell vaccine induces antigen-specific CD8+ T cells that are metabolically distinct from those of peptide vaccine and is well-combined with PD-1 checkpoint blockade
Nagaoka, K., Hosoi, A., Iino, T., Morishita, Y., Matsushita, H., & Kakimi, K. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1395124 · Cited by 38
Perspectives of Reprogramming Breast Cancer Metabolism
Wang, Y.-P., & Lei, Q. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-6020-5_10 · Cited by 39
Targeting the tumor microenvironment and T cell metabolism for effective cancer immunotherapy
Hope, H. C., & Salmond, R. J. (2019) · European Journal of Immunology · doi:10.1002/eji.201848058 · Cited by 38
Non-coding RNAs rewire cancer metabolism networks
Lin, X., Wu, Z., Hu, H., Luo, M., & Song, E. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.12.019 · Cited by 37
Resistance to immune checkpoint inhibitors in gastric cancer
Liu, K., Yuan, S., Wang, C., & Zhu, H. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1285343 · Cited by 36
EGFR-Driven Lung Adenocarcinomas Co-opt Alveolar Macrophage Metabolism and Function to Support EGFR Signaling and Growth
Kuhlmann-Hogan, A., Cordes, T., Xu, Z. Z., Kuna, R. S., Traina, K. A., Robles-Oteíza, C., Ayeni, D. O., Kwong, E. M., Levy, S., Globig, A.-M., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0434 · Cited by 39
Self-citation
Metabolic Reprogramming of Glycolysis, Lipids, and Amino Acids in Tumors: Impact on CD8 + T Cell Function and Targeted Therapeutic Strategies
Liang, P., Li, Z., Chen, Z., Chen, Z., Jin, T., He, F., Chen, X., Gou, H., & Yang, K. (2025) · The FASEB Journal · doi:10.1096/fj.202403019r · Cited by 42
The impact of tumor cell metabolism on T cell-mediated immune responses and immuno-metabolic biomarkers in cancer
Noel, G. L., Fontsa, M. L., & Willard-Gallo, K. E. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.03.003 · Cited by 35
Pyruvate Kinase M2: a Metabolic Bug in Re-Wiring the Tumor Microenvironment
Rihan, M., Nalla, L. V., Dharavath, A., Shard, A., Kalia, K., & Khairnar, A. (2019) · Cancer Microenvironment · doi:10.1007/s12307-019-00226-0 · Cited by 39
Cell Intrinsic and Systemic Metabolism in Tumor Immunity and Immunotherapy
Coleman, M. F., Cozzo, A. J., Pfeil, A. J., Etigunta, S. K., & Hursting, S. D. (2020) · Cancers · doi:10.3390/cancers12040852 · Cited by 37
Endoplasmic Reticulum Calcium Pumps and Tumor Cell Differentiation
Papp, B., Launay, S., Gélébart, P., Arbabian, A., Enyedi, Á., Brouland, J., Carosella, E. D., & Adle‐Biassette, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093351 · Cited by 39
Reprogramming of central carbon metabolism in hepatocellular carcinoma
Xia, H., Huang, Z., Xu, Y., Yam, J. W. P., & Cui, Y. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113485 · Cited by 40
Cell-Membrane-Anchored DNA Logic-Gated Nanoassemblies for In Situ Extracellular Bioimaging
Gong, H., Dai, Q., & Peng, P. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c13735 · Cited by 36
PCK1 dysregulation in cancer: Metabolic reprogramming, oncogenic activation, and therapeutic opportunities
Jin, X., Wang, K., & Tang, N. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2022.02.010 · Cited by 35
The development of CD8 T-cell exhaustion heterogeneity and the therapeutic potentials in cancer
Zhang, J., Lei, F., & Tan, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1166128 · Cited by 39
Taming Tumor Glycolysis and Potential Implications for Immunotherapy
Ganapathy‐Kanniappan, S. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00036 · Cited by 35
Survival of the fittest: Cancer challenges T cell metabolism
Franchina, D. G., HeFeng, F. Q., & Brenner, D. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.10.014 · Cited by 34
The Metabolic Profile of Tumor and Virally Infected Cells Shapes Their Microenvironment Counteracting T Cell Immunity
Magalhaes, I., Yogev, O., Mattsson, J., & Schurich, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02309 · Cited by 34
The Many Facets of Tumor Heterogeneity: Is Metabolism Lagging Behind?
Loponte, S., Lovisa, S., Deem, A. K., Carugo, A., & Viale, A. (2019) · Cancers · doi:10.3390/cancers11101574 · Cited by 36
Phosphoenolpyruvate from Glycolysis and PEPCK Regulate Cancer Cell Fate by Altering Cytosolic Ca2+
Moreno-Felici, J., Hyroššová, P., Aragó, M., Rodríguez‐Arévalo, S., García-Rovés, P. M., Escolano, C., & Perales, J. C. (2019) · Cells · doi:10.3390/cells9010018 · Cited by 36
Self-citation
Immunometabolism in fungal infections: the need to eat to compete
Weerasinghe, H., & Traven, A. (2020) · Current Opinion in Microbiology · doi:10.1016/j.mib.2020.07.001 · Cited by 36
Metabolic but not transcriptional regulation by PKM2 is important for natural killer cell responses
Walls, J. F., Subleski, J. J., Palmieri, E. M., Gonzalez-Cotto, M., Gardiner, C. M., McVicar, D. W., & Finlay, D. K. (2020) · eLife · doi:10.7554/elife.59166 · Cited by 35
Hematopoietic versus Solid Cancers and T Cell Dysfunction: Looking for Similarities and Distinctions
Montironi, C., Muñoz‐Pinedo, C., & Eldering, E. (2021) · Cancers · doi:10.3390/cancers13020284 · Cited by 38
Immunometabolism at the Nexus of Cancer Therapeutic Efficacy and Resistance
Traba, J., Sack, M. N., Waldmann, T. A., & Antón, O. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.657293 · Cited by 39
Immunometabolism: Towards a Better Understanding the Mechanism of Parasitic Infection and Immunity
Chen, J.-Y., Zhou, J., & Pan, W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.661241 · Cited by 40
Clinical Significance of the Duality of Wnt/β-Catenin Signaling in Human Hepatocellular Carcinoma
Aoki, T., Nishida, N., & Kudo, M. (2022) · Cancers · doi:10.3390/cancers14020444 · Cited by 35
Reconciling environment-mediated metabolic heterogeneity with the oncogene-driven cancer paradigm in precision oncology
Linden, C. V., & Corbet, C. (2019) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2019.05.016 · Cited by 34
Metabolic profiles of regulatory T cells in the tumour microenvironment
Rao, D., Verburg, F., Renner, K., Peeper, D. S., Lacroix, R., & Blank, C. U. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02881-z · Cited by 43
Multimodal Molecular Imaging Detects Early Responses to Immune Checkpoint Blockade
Saida, Y., Brender, J., Yamamoto, K., Mitchell, J. B., Krishna, M. C., & Kishimoto, S. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3182 · Cited by 38
Dynamic polarization of tumor-associated macrophages and their interaction with intratumoral T cells in an inflamed tumor microenvironment: from mechanistic insights to therapeutic opportunities
Han, J., Dong, L., Wu, M., & Ma, F. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1160340 · Cited by 36
Screening in serum-derived medium reveals differential response to compounds targeting metabolism
Abbott, K. L., Ali, A., Casalena, D. E., Do, B. T., Ferreira, R., Cheah, J. H., Soule, C. K., Deik, A., Kunchok, T., Schmidt, D. R., et al. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2023.08.007 · Cited by 35
Altered Metabolism in Glioblastoma: Myeloid-Derived Suppressor Cell (MDSC) Fitness and Tumor-Infiltrating Lymphocyte (TIL) Dysfunction
Ianni, N. D., Musio, S., & Pellegatta, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094460 · Cited by 34
Targeting regulatory T cells in gastric cancer: Pathogenesis, immunotherapy, and prognosis
Wang, B., Zhang, Z., Liu, W., & Tan, B. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114180 · Cited by 38
Acidity‐mediated induction of FoxP3 + regulatory T cells
Rao, D., Stunnenberg, J. A., Lacroix, R., Dimitriadis, P., Kaplon, J., Verburg, F., van Royen, P. T., Hoefsmit, E. P., Renner, K., Blank, C. U., et al. (2023) · European Journal of Immunology · doi:10.1002/eji.202250258 · Cited by 33
Mitochondrial dysfunctions in T cells: focus on inflammatory bowel disease
Lee, H., Jeon, J., & Kim, E. S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1219422 · Cited by 33
PPARβ/δ-orchestrated metabolic reprogramming supports the formation and maintenance of memory CD8 + T cells
Bevilacqua, A., Franco, F., Lu, Y.-T., Rahiman, N., Kao, K., Chuang, Y., Zhu, Y., Held, W., Xie, X., Gunsalus, K. C., et al. (2024) · Science Immunology · doi:10.1126/sciimmunol.adn2717 · Cited by 33
Self-citation
Metabolic reprogramming of CAR T cells: a new frontier in cancer immunotherapy
Frlic, T., & Pavlin, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1688995 · Cited by 38
Immunometabolic cross-talk in the inflamed heart
Marelli‐Berg, F. M., & Aksentijević, D. (2019) · Cell Stress · doi:10.15698/cst2019.08.194 · Cited by 36
Inhibition of Glycolysis in Pathogenic TH17 Cells through Targeting a miR-21–Peli1–c-Rel Pathway Prevents Autoimmunity
Qiu, R., Yu, X., Wang, L., Han, Z., Yao, C., Cui, Y., Hou, G., Dai, D., Jin, W., & Shen, N. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000060 · Cited by 36
Heterogeneity of Glucose Transport in Lung Cancer
Martinez, C. A., & Scafoglio, C. (2020) · Biomolecules · doi:10.3390/biom10060868 · Cited by 35
Arginase Therapy Combines Effectively with Immune Checkpoint Blockade or Agonist Anti-OX40 Immunotherapy to Control Tumor Growth
Badeaux, M. D., Rolig, A. S., Agnello, G., Enzler, D., Kasiewicz, M. J., Priddy, L., Wiggins, J. F., Muir, A., Sullivan, M. R., Cleef, J. V., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0317 · Cited by 35
Characterization of hypoxia response patterns identified prognosis and immunotherapy response in bladder cancer
Cao, R., Ma, B., Wang, G., Xiong, Y., Tian, Y., & Yuan, L. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.06.011 · Cited by 33
Phosphoenolpyruvate regulates the Th17 transcriptional program and inhibits autoimmunity
Huang, T.-Y., Hirota, M., Sasaki, D., Kalra, R. S., Chien, H.-C., Tamai, M., Sarkar, S., Mi, Y., Miyagi, M., Seto, Y., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112205 · Cited by 33
The role of noncoding RNAs in metabolic reprogramming of cancer cells
Safi, A., Saberiyan, M., Sanaei, M., Adelian, S., Asl, F. D., Zeinaly, M., Shamsi, M., & Ahmadi, R. (2023) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-023-00447-8 · Cited by 36
Tumor-derived factors affecting immune cells
Russo, V. E. A., & Protti, M. P. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.06.005 · Cited by 33
Fatty Acid Uptake in T Cell Subsets Using a Quantum Dot Fatty Acid Conjugate
Muroski, M. E., Miska, J. M., Chang, A. L., Zhang, P., Rashidi, A., Moore, H. C., Lopez‐Rosas, A., Han, Y., & Lesniak, M. S. (2017) · Scientific Reports · doi:10.1038/s41598-017-05556-x · Cited by 33
The mechanistic insights of the antioxidant Keap1-Nrf2 pathway in oncogenesis: a deadly scenario
Mukherjee, A. G., & Gopalakrishnan, A. V. (2023) · Medical Oncology · doi:10.1007/s12032-023-02124-4 · Cited by 33
Enolase represents a metabolic checkpoint controlling the differential exhaustion programmes of hepatitis virus-specific CD8 + T cells
Winkler, F., Hipp, A. V., Ramírez, C. D., Martin, B., Villa, M., Neuwirt, E., Gorka, O., Aerssens, J., Johansson, S. E., Rana, N., et al. (2023) · Gut · doi:10.1136/gutjnl-2022-328734 · Cited by 32
Why Treg should be the focus of cancer immunotherapy: The latest thought
Liu, Z., Zhou, J., Shi-hui, W., Chen, Z., Wu, S., Chen, L., Zhu, X. M., & Li, Z. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115142 · Cited by 35
One-carbon metabolism shapes T cell immunity in cancer
Qiu, Y., Xie, E., Xu, H., Cheng, H., & Li, G. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.05.010 · Cited by 33
Metabolic reprogramming of the tumor microenvironment to enhance immunotherapy
Lim, S. A. (2024) · BMB Reports · doi:10.5483/bmbrep.2024-0031 · Cited by 35
Hematopoietic stem cell lineage specification
Pouzolles, M., Oburoglu, L., Taylor, N. N., & Zimmermann, V. S. (2016) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000260 · Cited by 37
T Cell Calcium Signaling Regulation by the Co-Receptor CD5
Freitas, C. M. T., Johnson, D. K., & Weber, K. S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051295 · Cited by 32
Adenosine leakage from perforin-burst extracellular vesicles inhibits perforin secretion by cytotoxic T-lymphocytes
Tadokoro, H., Hirayama, A., Kudo, R., Hasebe, M., Yoshioka, Y., Matsuzaki, J., Yamamoto, Y., Sugimoto, M., Soga, T., & Ochiya, T. (2020) · PLoS ONE · doi:10.1371/journal.pone.0231430 · Cited by 32
Targeting Immunometabolism in Glioblastoma
Mohan, A. A., Tomaszewski, W. H., Haskell-Mendoza, A. P., Hotchkiss, K. M., Singh, K., Reedy, J. L., Fecci, P. E., Sampson, J. H., & Khasraw, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.696402 · Cited by 34
Tumor Microenvironment-Derived Metabolites: A Guide to Find New Metabolic Therapeutic Targets and Biomarkers
García‐Cañaveras, J. C., & Lahoz, A. (2021) · Cancers · doi:10.3390/cancers13133230 · Cited by 33
A CD10‐OGP Membrane Peptolytic Signaling Axis in Fibroblasts Regulates Lipid Metabolism of Cancer Stem Cells via SCD1
Yu, S., Lu, Y., Su, A., Chen, J., Li, J., Zhou, B., Liu, X., Xia, Q., Li, Y., Li, J., et al. (2021) · Advanced Science · doi:10.1002/advs.202101848 · Cited by 32
Self-citation
A Potential “Anti-Warburg Effect” in Circulating Tumor Cell-mediated Metastatic Progression?
Jiang, Z., He, J., Zhang, B., Wang, L., Long, C., Zhao, B., Yang, Y., Du, L., Luo, W., Hu, J., et al. (2024) · Aging and Disease · doi:10.14336/ad.2023.1227 · Cited by 32
Glucose metabolism and tumour microenvironment in pancreatic cancer: A key link in cancer progression
Dong, S., Li, W., Li, X., Wang, Z., Zhou, C., Shi, H., He, R., Chen, C., & Zhou, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1038650 · Cited by 33
Immunosurveillance encounters cancer metabolism
Chuang, Y., Tzeng, S., Ho, P., & Tsai, C. (2024) · EMBO Reports · doi:10.1038/s44319-023-00038-w · Cited by 33
Self-citation
Dynamic glycolytic reprogramming effects on dendritic cells in pancreatic ductal adenocarcinoma
Zhang, B., Ohuchida, K., Tsutsumi, C., Shimada, Y., Mochida, Y., Oyama, K., Iwamoto, C., Sheng, N., Fei, S., Shindo, K., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03192-8 · Cited by 34
New horizons in our understanding of precursor multiple myeloma and early interception
dos Santos, D. M. C., Toenges, R., Bertamini, L., Alberge, J.-B., & Ghobrial, I. M. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00755-x · Cited by 34
Metabolic engineering to facilitate anti-tumor immunity
Schild, T., Wallisch, P., Zhao, Y., Wang, Y., Haughton, L., Chirayil, R., Pierpont, K., Chen, K., Violante, S. N., Cross, J. R., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.02.004 · Cited by 32
Chrono-controlled hydrogel platform orchestrates metabolic reprogramming and cuproptosis-driven immune activation against triple-negative breast cancer
Lu, Y., Pan, Q., Luo, K., He, B., & Pu, Y. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123568 · Cited by 32
Changing perspective on oncometabolites: from metabolic signature of cancer to tumorigenic and immunosuppressive agents
Corrado, M., Scorrano, L., & Campello, S. (2016) · Oncotarget · doi:10.18632/oncotarget.8727 · Cited by 31
Metabolism – A cornerstone of cancer initiation, progression, immune evasion and treatment response
Lunt, S. Y., & Fendt, S. (2017) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2017.12.006 · Cited by 30
T Cell Metabolism in Cancer Immunotherapy
Aksoylar, H., Tijaro-Ovalle, N. M., Boussiotis, V. A., & Patsoukis, N. (2020) · Immunometabolism · doi:10.20900/immunometab20200020 · Cited by 31
Metabolites Profiling of Melanoma Interstitial Fluids Reveals Uridine Diphosphate as Potent Immune Modulator Capable of Limiting Tumor Growth
Vecchio, E., Caiazza, C., Mimmi, S., Avagliano, A., Iaccino, E., Brusco, T., Nisticò, N., Maisano, D., Aloisio, A., Quinto, I., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.730726 · Cited by 31
Reprogramming of tissue metabolism during cancer metastasis
Ganguly, K., & Kimmelman, A. C. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.02.005 · Cited by 32
Redox modulation with a perfluorocarbon nanoparticle to reverse Treg-mediated immunosuppression and enhance anti-tumor immunity
Li, Z., Deng, Y., Sun, H., Tan, C., Li, H., Mo, F., Wang, Y., Li, J., Zhou, Z., & Sun, M. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.05.013 · Cited by 30
CAR-T treatment for cancer: prospects and challenges
Chen, R., Chen, L., Wang, C., Zhu, H., Gu, L., Li, Y., Xiong, X., Chen, G., & Jian, Z. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1288383 · Cited by 33
Urine scRNAseq reveals new insights into the bladder tumor immune microenvironment
Tran, M. A., Youssef, D., Shroff, S., Chowhan, D., Beaumont, K. G., Sebra, R., Mehrazin, R., Wiklund, P. N., Lin, J. J., Horowitz, A., et al. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20240045 · Cited by 32
Metabolism-driven posttranslational modifications and immune regulation: Emerging targets for immunotherapy
Wu, G., Fan, X., Cheng, L., Chen, Z., Yi, Y., Liang, J., Huang, X., Yang, N., Yin, J., Guo, W., et al. (2025) · Science Advances · doi:10.1126/sciadv.adx6489 · Cited by 37
Regulation of T cell exhaustion and stemness: molecular mechanisms and implications for cancer immunotherapy
Chen, Z., Zhu, Z., Hu, T., Yao, C., & Wu, T. (2025) · Cellular and Molecular Immunology · doi:10.1038/s41423-025-01378-4 · Cited by 37
Preclinical models for interrogating drug action in human cancers using Stable Isotope Resolved Metabolomics (SIRM)
Lane, A. N., Higashi, R. M., & Fan, T. W. ‐. (2016) · Metabolomics · doi:10.1007/s11306-016-1065-y · Cited by 32
Recent challenges and advances in genetically-engineered cell therapy
Yong, S., Chung, J. Y., Song, Y., & Kim, Y. (2017) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-017-0381-1 · Cited by 30
Intricate Regulation of Phosphoenolpyruvate Carboxykinase (PEPCK) Isoforms in Normal Physiology and Disease
Seenappa, V., Joshi, M. B., & Satyamoorthy, K. (2019) · Current Molecular Medicine · doi:10.2174/1566524019666190404155801 · Cited by 31
Reduced CTL motility and activity in avascular tumor areas
Manaster, Y., Shipony, Z., Hutzler, A., Kolesnikov, M., Avivi, C., Shalmon, B., Barshack, I., Besser, M. J., Feferman, T., & Shakhar, G. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02361-5 · Cited by 29
Metabolites in the Tumor Microenvironment Reprogram Functions of Immune Effector Cells Through Epigenetic Modifications
Li, Y., Wu, Y., & Hu, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.641883 · Cited by 31
Drug delivery for metabolism targeted cancer immunotherapy
Khodaei, T., Inamdar, S., Suresh, A. P., & Acharya, A. P. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114242 · Cited by 30

Authors: Ho, P.-C., Bihuniak, J. D., Macintyre, A. N., Staron, M., Liu, X., Amezquita, R., Tsui, Y.-C., Cui, G., Micevic, G., Perales, J. C., Kleinstein, S. H., Abel, E. D., Insogna, K. L., Feske, S., Locasale, J. W., Bosenberg, M. W., Rathmell, J. C., & Kaech, S. M.
Affiliations: Yale University (US)
Duke University (US)
Cornell University (US)
Howard Hughes Medical Institute (US)
Institut d'Investigació Biomédica de Bellvitge (ES)
University of Iowa (US)
NYU Langone Health (US)
Corresponding author: Ho, Ping-Chih
Kaech, Susan M.
ORCID: Ho, Ping-Chih
Bihuniak, Jessica Dauz
Macintyre, Andrew N.
Liu, Xiaojing
Amezquita, Robert
Cui, Guoliang
Micevic, Goran
Perales, Jose C.
Kleinstein, Steven H.
Abel, E. Dale
Insogna, Karl L.
Feske, Stefan
Locasale, Jason W.
Bosenberg, Marcus W.
Rathmell, Jeffrey C.
Kaech, Susan M.
Venue: Cell
Publisher: Elsevier BV
Published: 2015-09
Volume: 162
Issue: 6
Pages: 1217-1228
ISSN: 0092-8674 (ISSN-L)
DOI: 10.1016/j.cell.2015.08.012
PMC: PMC4567953
OpenAlex: W2160551785
Cited by: 1,462
References: 47
Citations by year: 2026: 125 · 2025: 148 · 2024: 127 · 2023: 147 · 2022: 155 · 2021: 168 · 2020: 156 · 2019: 116 · 2018: 116 · 2017: 110 · 2016: 84 · 2015: 10
FWCI: 35.25
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 375 d)
Locations: Cell (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: Howard Hughes Medical Institute
National Heart, Lung, and Blood Institute (R01HL108006)
National Cancer Institute (R00CA168997, R01CA123350, F30CA196089, P50CA121974, P30CA016359)
National Institute of General Medical Sciences (T32GM007205)
National Institute of Allergy and Infectious Diseases (R01AI110613, R37AI066232, R01AI063345, R01AI097302, R01AI074699, R01AI066232)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (P30AR053495)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords: phosphoenolpyruvate, T cell metabolism, tumor-infiltrating T cells, aerobic glycolysis, tumor microenvironment, PCK1, SERCA, calcium signaling, NFAT, T cell effector function, metabolic reprogramming, antitumor immunity, melanoma, immunotherapy
MeSH terms: Animals, Calcium, Endoplasmic Reticulum, Glycolysis, Hexokinase, Immunotherapy, Melanoma, Phosphoenolpyruvate, Receptors, Antigen, T-Cell, Monitoring, Immunologic, Signal Transduction, CD4-Positive T-Lymphocytes, Transforming Growth Factor beta, Lymphocytes, Tumor-Infiltrating, NFATC Transcription Factors, Mice, Sarcoplasmic Reticulum Calcium-Transporting ATPases, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks